Soros Capital Management LLC Buys 5,970 Shares of Zoetis Inc. (NYSE:ZTS)

Soros Capital Management LLC lifted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 82.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 13,211 shares of the company's stock after purchasing an additional 5,970 shares during the quarter. Soros Capital Management LLC's holdings in Zoetis were worth $2,152,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Mission Wealth Management LP increased its position in shares of Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock worth $479,000 after acquiring an additional 59 shares in the last quarter. VeraBank N.A. boosted its stake in Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after purchasing an additional 62 shares during the period. HUB Investment Partners LLC grew its position in Zoetis by 4.7% during the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after purchasing an additional 62 shares in the last quarter. Procyon Advisors LLC raised its stake in Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock valued at $768,000 after purchasing an additional 63 shares during the period. Finally, Deseret Mutual Benefit Administrators lifted its holdings in shares of Zoetis by 6.6% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock valued at $170,000 after purchasing an additional 65 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insider Transactions at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares of the company's stock, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ZTS. Piper Sandler lifted their price target on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Thursday, February 27th. StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Stifel Nicolaus decreased their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Finally, Barclays increased their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Zoetis currently has a consensus rating of "Buy" and a consensus target price of $214.40.

Zoetis Stock Up 0.7 %

Shares of ZTS stock traded up $1.09 on Wednesday, hitting $151.08. The company's stock had a trading volume of 2,093,141 shares, compared to its average volume of 2,522,363. The stock has a market capitalization of $67.41 billion, a price-to-earnings ratio of 27.62, a P/E/G ratio of 2.78 and a beta of 0.92. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The firm's fifty day moving average price is $159.06 and its 200-day moving average price is $169.10. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.32%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio is 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.